Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 1
1995 4
1997 3
1998 3
1999 5
2000 5
2001 10
2002 7
2003 8
2004 7
2005 15
2006 11
2007 7
2008 8
2009 8
2010 16
2011 10
2012 8
2013 23
2014 20
2015 12
2016 8
2017 14
2018 15
2019 15
2020 16
2021 14
2022 11
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Antidepressants or running therapy: Comparing effects on mental and physical health in patients with depression and anxiety disorders.
Verhoeven JE, Han LKM, Lever-van Milligen BA, Hu MX, Révész D, Hoogendoorn AW, Batelaan NM, van Schaik DJF, van Balkom AJLM, van Oppen P, Penninx BWJH. Verhoeven JE, et al. J Affect Disord. 2023 May 15;329:19-29. doi: 10.1016/j.jad.2023.02.064. Epub 2023 Feb 23. J Affect Disord. 2023. PMID: 36828150 Free article. Clinical Trial.
BACKGROUND: Antidepressant medication and running therapy are both effective treatments for patients with depressive and anxiety disorders. However, they may work through different pathophysiological mechanisms and could differ in their impact on physical health. ...METHOD …
BACKGROUND: Antidepressant medication and running therapy are both effective treatments for patients with depressive and anxiety diso …
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Walkup JT, et al. N Engl J Med. 2008 Dec 25;359(26):2753-66. doi: 10.1056/NEJMoa0804633. Epub 2008 Oct 30. N Engl J Med. 2008. PMID: 18974308 Free PMC article. Clinical Trial.
METHODS: In this randomized, controlled trial, we assigned 488 children between the ages of 7 and 17 years who had a primary diagnosis of separation anxiety disorder, generalized anxiety disorder, or social phobia to receive 14 sessions of cognitive behavioral thera …
METHODS: In this randomized, controlled trial, we assigned 488 children between the ages of 7 and 17 years who had a primary diagnosis of se …
Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Slee A, et al. Lancet. 2019 Feb 23;393(10173):768-777. doi: 10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31. Lancet. 2019. PMID: 30712879
BACKGROUND: Generalised anxiety disorder is a disease that can be associated with substantial dysfunction. ...INTERPRETATION: To our knowledge, this is the largest contemporary review of pharmacological agents for the treatment of generalised anxiety disorder by use …
BACKGROUND: Generalised anxiety disorder is a disease that can be associated with substantial dysfunction. ...INTERPRETATION: To our …
Sertraline versus other antidepressive agents for depression.
Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Cipriani A, et al. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117. doi: 10.1002/14651858.CD006117.pub4. Cochrane Database Syst Rev. 2010. PMID: 20393946 Free PMC article. Review.
SEARCH STRATEGY: MEDLINE (1966 to 2008), EMBASE (1974 to 2008), the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to July 2008. ...MAIN RESULTS: A total of 59 studies, mostly of …
SEARCH STRATEGY: MEDLINE (1966 to 2008), EMBASE (1974 to 2008), the Cochrane Collaboration Depression, Anxiety and Neurosis Controlle …
Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis.
Wang Z, Whiteside SPH, Sim L, Farah W, Morrow AS, Alsawas M, Barrionuevo P, Tello M, Asi N, Beuschel B, Daraz L, Almasri J, Zaiem F, Larrea-Mantilla L, Ponce OJ, LeBlanc A, Prokop LJ, Murad MH. Wang Z, et al. JAMA Pediatr. 2017 Nov 1;171(11):1049-1056. doi: 10.1001/jamapediatrics.2017.3036. JAMA Pediatr. 2017. PMID: 28859190 Free PMC article. Review.
When CBT was compared with wait-listing/no treatment, CBT significantly improved primary anxiety symptoms, remission, and response. Cognitive behavioral therapy reduced primary anxiety symptoms more than fluoxetine and improved remission more than sertraline. …
When CBT was compared with wait-listing/no treatment, CBT significantly improved primary anxiety symptoms, remission, and response. C …
Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P. Zhou X, et al. Lancet Psychiatry. 2020 Jul;7(7):581-601. doi: 10.1016/S2215-0366(20)30137-1. Lancet Psychiatry. 2020. PMID: 32563306 Free PMC article.
In terms of acceptability, nefazodone and fluoxetine were associated with fewer dropouts than sertraline, imipramine, and desipramine (ORs ranged from 0.17 to 0.50); imipramine was associated with more dropouts than pill placebo, desvenlafaxine, fluoxetine plus CBT, and vi …
In terms of acceptability, nefazodone and fluoxetine were associated with fewer dropouts than sertraline, imipramine, and desipramine …
Efficacy of omega-3 supplementation on sertraline continuous therapy to reduce depression or anxiety symptoms: A systematic review and meta-analysis.
Chambergo-Michilot D, Brañez-Condorena A, Falvy-Bockos I, Pacheco-Mendoza J, Benites-Zapata VA. Chambergo-Michilot D, et al. Psychiatry Res. 2021 Feb;296:113652. doi: 10.1016/j.psychres.2020.113652. Epub 2020 Dec 15. Psychiatry Res. 2021. PMID: 33348198 Review.
We aimed to synthesize the evidence from randomized controlled trials (RCTs) that determined the efficacy of adding omega-3 supplementation to the continuous sertraline therapy in adults with depression. Meta-analyses were performed using random effects. ...A subgroup anal …
We aimed to synthesize the evidence from randomized controlled trials (RCTs) that determined the efficacy of adding omega-3 supplementation …
The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C, Gilbody S, Fawsitt C, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Khan N, Lanham P, Pervin J, Peters TJ, Riozzie D, Salaminios G, Thomas L, Welton NJ, Wiles N, Woodhouse R, Lewis G. Lewis G, et al. Lancet Psychiatry. 2019 Nov;6(11):903-914. doi: 10.1016/S2215-0366(19)30366-9. Epub 2019 Sep 19. Lancet Psychiatry. 2019. PMID: 31543474 Free PMC article. Clinical Trial.
However, for secondary outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better mental (but not physical) health-related quality of life, and self-reported improvements in mental health. ...INTERPRETATION: Sertraline is unlikely to …
However, for secondary outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better mental (but not phy …
Maintenance or Discontinuation of Antidepressants in Primary Care.
Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, Mangin D, King M, Lanham P, Moore M, Nazareth I, Wiles N, Bacon F, Bird M, Brabyn S, Burns A, Clarke CS, Hunt A, Pervin J, Lewis G. Lewis G, et al. N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356. N Engl J Med. 2021. PMID: 34587384 Clinical Trial.
The primary outcome was the first relapse of depression during the 52-week trial period, as evaluated in a time-to-event analysis. Secondary outcomes were depressive and anxiety symptoms, physical and withdrawal symptoms, quality of life, time to stopping an antidepressant …
The primary outcome was the first relapse of depression during the 52-week trial period, as evaluated in a time-to-event analysis. Secondary …
Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors.
Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T. Dahl AA, et al. Acta Psychiatr Scand. 2005 Jun;111(6):429-35. doi: 10.1111/j.1600-0447.2005.00529.x. Acta Psychiatr Scand. 2005. PMID: 15877709 Clinical Trial.
OBJECTIVE: The objective was to study the efficacy of sertraline on symptoms of psychic and somatic anxiety in patients suffering from moderate-to-severe generalized anxiety disorder (GAD). ...Reduction of secondary depressive symptoms was more correlated wit …
OBJECTIVE: The objective was to study the efficacy of sertraline on symptoms of psychic and somatic anxiety in patients suffer …
256 results